Lanstead Alternate Financing - Australia

Bare Bones of Alternate Financing

October 17, 2017 / POSTED BY / CATEGORY: Articles

When capital markets are difficult, as the last few years have been for resource companies, alternative financings become an increasingly popular source of capital. It is largely because traditional equity finance has dried up and alternative financings are often readily available. This allows small and mid-cap companies to continue to…

READ MORE

Lanstead United Kingdom Announcement

Lanstead provides £5m to AIM Quoted ImmuPharma to support the pivotal Phase III clinical trial of Lupuzor™

October 4, 2017 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead is pleased to announce that its Sharing Agreement with AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) (“ImmuPharma” or the “Company”) has been successfully completed, with ImmuPharma having received over £5 million from Lanstead, £600,000 more than was originally subscribed, through the…

READ MORE

Lanstead Australia Announcement

Lanstead invests A$10 million in support of Rett syndrome Phase 3 trial

June 29, 2017 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its A$10 million investment in Australian biotechnology firm Neuren Pharmaceuticals Ltd (“Neuren”) (ASX: NEU) ahead of an upcoming Rett syndrome Phase 3 trial. Neuren is developing novel new therapies for brain injuries, neurodevelopmental and neurodegenerative disorders. It currently has a clinical stage molecule,…

READ MORE


Lanstead Australia Announcement

Lanstead invests A$4 million to support SmartTrans’ e-commerce and SmartPay

December 28, 2016 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its A$4 million investment in SmartTrans Holdings Limited (“SmartTrans”) (ASX: SMA) to fund the expansion of their e-commerce platforms and facilitate the rollout of their SmartPay payments platform in Australia and China. SmartTrans recently announced a Memorandum of Understanding (MOU) with Shanghai Stock…

READ MORE

Lanstead United Kingdom Announcement

Lanstead Invests £4.4 million in ImmuPharma PLC in support of Lupuzora™ phase 3 trial

February 5, 2016 / POSTED BY / CATEGORY: Announcements

Global investment firm Lanstead has today announced its £4.4 million investment in AIM quoted, specialist drug discovery and development company, ImmuPharma plc (AIM: IMM) as the business looks to commence its pivotal Phase III clinical trial of Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, the…

READ MORE